Opus Genetics (IRD) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

IRD · Stock Price

USD 5.36+4.41 (+464.21%)

Market Cap: $363.7M

Historical price data

Overview

Opus Genetics is on a mission to develop and deliver transformative gene therapies for patients with inherited retinal diseases, a leading cause of blindness. The company has advanced its lead candidate, OPGx-LCA5, into a Phase 1/2 clinical trial for LCA5-mediated Leber congenital amaurosis, built upon a platform validated by foundational research from UPenn. Its strategy employs a focused subsidiary model to drive program-specific agility and is supported by public market funding. Opus aims to address high-unmet-need, monogenic retinal conditions with a targeted pipeline designed to demonstrate proof-of-concept and expand into broader indications.

OphthalmologyInherited Retinal Diseases

Technology Platform

AAV (adeno-associated virus) vector-based gene delivery platform optimized for targeting specific retinal cell types, built upon foundational research from the University of Pennsylvania.

Opportunities

The collective market for inherited retinal diseases represents a significant unmet need with potential for high-value, one-time therapies.

Success with a lead program like OPGx-LCA5 can validate the platform and create opportunities to expand into other genetic forms of blindness, either internally or through strategic partnerships.

Risk Factors

The company faces high clinical development risk with its lead candidate in early-stage trials, substantial financial risk requiring future dilutive capital raises, and the technical challenges of AAV gene therapy manufacturing and immunogenicity.

Competition from larger, better-funded biopharma firms is also a key threat.

Competitive Landscape

Opus competes in a crowded ophthalmology gene therapy space against large biopharma (e.g., Roche), established gene therapy biotechs, and other IRD-focused firms. Its competitive edge lies in its focused pipeline targeting specific underserved genetic subtypes (LCA5, NR2E3) and its foundational IP from the University of Pennsylvania, allowing it to avoid direct competition in more common targets.

More companies in United States →